Exact Sciences Unveils Promising Oncodetect MRD Test Results in Early Triple-Negative Breast Cancer Study

Reuters12-12

Exact Sciences Unveils Promising Oncodetect MRD Test Results in Early Triple-Negative Breast Cancer Study

Exact Sciences Corporation has announced results from the first clinical study of its Oncodetect® molecular residual disease (MRD) test in early triple-negative breast cancer (TNBC). The data, presented at the San Antonio Breast Cancer Symposium (SABCS), show that the Oncodetect test strongly predicts distant recurrence following surgery in patients with early TNBC. The substudy, conducted in collaboration with the NSABP Foundation and the German Breast Group as part of the NSABP-B-59/GBG-96-GeparDouze trial, evaluated circulating tumor DNA (ctDNA) in blood samples collected before treatment and after surgery. Results demonstrated the test's ability to help identify patients at higher risk of recurrence, supporting its potential role in informing post-surgical treatment decisions. Exact Sciences intends to submit the data for peer-reviewed publication and to MolDx in support of Medicare coverage.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. EXACT Sciences Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20251211912129) on December 11, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2590423385?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-12 06:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590423385","market":"nz","top_or_hot":-1,"title":"Exact Sciences Unveils Promising Oncodetect MRD Test Results in Early Triple-Negative Breast Cancer Study","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Exact Sciences Unveils Promising Oncodetect MRD Test Results in Early Triple-Negative Breast Cancer Study\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Exact Sciences Corporation has announced results from the first clinical study of its Oncodetect® molecular residual disease (MRD) test in early triple-negative breast cancer (TNBC). The data, presented at the San Antonio Breast Cancer Symposium (SABCS), show that the Oncodetect test strongly predicts distant recurrence following surgery in patients with early TNBC. The substudy, conducted in collaboration with the NSABP Foundation and the German Breast Group as part of the NSABP-B-59/GBG-96-GeparDouze trial, evaluated circulating tumor DNA (ctDNA) in blood samples collected before treatment and after surgery. Results demonstrated the test's ability to help identify patients at higher risk of recurrence, supporting its potential role in informing post-surgical treatment decisions. Exact Sciences intends to submit the data for peer-reviewed publication and to MolDx in support of Medicare coverage.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. EXACT Sciences Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20251211912129) on December 11, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Exact Sciences Unveils Promising Oncodetect MRD Test Results in Early Triple-Negative Breast Cancer Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nExact Sciences Unveils Promising Oncodetect MRD Test Results in Early Triple-Negative Breast Cancer Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-12 06:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Exact Sciences Unveils Promising Oncodetect MRD Test Results in Early Triple-Negative Breast Cancer Study\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Exact Sciences Corporation has announced results from the first clinical study of its Oncodetect® molecular residual disease (MRD) test in early triple-negative breast cancer (TNBC). The data, presented at the San Antonio Breast Cancer Symposium (SABCS), show that the Oncodetect test strongly predicts distant recurrence following surgery in patients with early TNBC. The substudy, conducted in collaboration with the NSABP Foundation and the German Breast Group as part of the NSABP-B-59/GBG-96-GeparDouze trial, evaluated circulating tumor DNA (ctDNA) in blood samples collected before treatment and after surgery. Results demonstrated the test's ability to help identify patients at higher risk of recurrence, supporting its potential role in informing post-surgical treatment decisions. Exact Sciences intends to submit the data for peer-reviewed publication and to MolDx in support of Medicare coverage.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. EXACT Sciences Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20251211912129) on December 11, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2324357040.USD","symbol_name":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL59jZqz:1","article_id":"2590423385","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590423385","pubTimestamp":1765492215,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Exact Sciences Corporation has announced results from the first clinical study of its Oncodetect molecular residual disease  test in early triple-negative breast cancer . The data, presented at the San Antonio Breast Cancer Symposium , show that the Oncodetect test strongly predicts distant recurrence following surgery in patients with early TNBC. The substudy, conducted in collaboration with the NSABP Foundation and the German Breast Group as part of the NSABP-B-59/GBG-96-GeparDouze trial, evaluated circulating tumor DNA  in blood samples collected before treatment and after surgery. Results demonstrated the test's ability to help identify patients at higher risk of recurrence, supporting its potential role in informing post-surgical treatment decisions. Exact Sciences intends to submit the data for peer-reviewed publication and to MolDx in support of Medicare coverage.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","BK4588":"碎股","BK4139":"生物科技","BK4585":"ETF&股票定投概念","BK4548":"巴美列捷福持仓","LU1861558580.USD":"日兴方舟颠覆性创新基金B","EXAS":"精密科学"},"translate_title":"Exact Sciences在早期三阴性乳腺癌研究中公布了有希望的Oncodetect MRD测试结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EXAS":0.9},"content_text":"Exact Sciences Unveils Promising Oncodetect MRD Test Results in Early Triple-Negative Breast Cancer Study\n    \n\n        Exact Sciences Corporation has announced results from the first clinical study of its Oncodetect® molecular residual disease (MRD) test in early triple-negative breast cancer (TNBC). The data, presented at the San Antonio Breast Cancer Symposium (SABCS), show that the Oncodetect test strongly predicts distant recurrence following surgery in patients with early TNBC. The substudy, conducted in collaboration with the NSABP Foundation and the German Breast Group as part of the NSABP-B-59/GBG-96-GeparDouze trial, evaluated circulating tumor DNA (ctDNA) in blood samples collected before treatment and after surgery. Results demonstrated the test's ability to help identify patients at higher risk of recurrence, supporting its potential role in informing post-surgical treatment decisions. Exact Sciences intends to submit the data for peer-reviewed publication and to MolDx in support of Medicare coverage.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. EXACT Sciences Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20251211912129) on December 11, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2590423385","isCrawlerRequest":true}